wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q34488671-E622E005-5A81-481C-98C9-70F630653253
Q34488671-E622E005-5A81-481C-98C9-70F630653253
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34488671-E622E005-5A81-481C-98C9-70F630653253
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
P2860
Q34488671-E622E005-5A81-481C-98C9-70F630653253
BestRank
Statement
http://www.wikidata.org/entity/statement/Q34488671-E622E005-5A81-481C-98C9-70F630653253
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4499f0d21cb10a427e1a85d3d29b7e80a0d44b6b
P2860
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.